BioCentury

8:00 AM GMT, Dec 19, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulatory

Crofelemer regulatory update

Salix submitted an NDA to FDA for crofelemer to treat HIV-associated diarrhea. The submission comes just a month after Napo said it terminated a 2008 deal that gave Salix rights to crofelemer in North America,

Read the full 353 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.